Cell-Based Assays Market Size, Share, Growth Report 2032

Industry Perspective:

The global cell-based assays market size was evaluated at $16.3 Billion in 2022 and is slated to hit $26.5 Billion by the end of 2030 with a CAGR of nearly 12.4% between 2023 and 2030.

Request Free Sample

The market report is an indispensable guide on growth factors, challenges, restraints, and opportunities in the global marketspace. The cell-based assay industry report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, market attractiveness analysis, PESTEL analysis, SWOT analysis, Porter’s five force analysis, and value chain analysis. Additionally, the report explores the investor and stakeholder space to help companies make data-driven decisions.

Cell-Based Assays Market: Overview

Cell-based assays help in determining the proficiency of compounds in a cellular environment. This, in turn, is key in understanding compound behaviors in a biological ecosystem and bringing into line data with a translatable biomarker. Cellular assays can find applications in biomedical activities and drug-discovery testing for proficiently measuring cytotoxicity, biological activities, biochemical machines, and off-target interactions. The benefits of using cell-based assays are the facilitation & generation of complex and biologically relevant information. Unlike conventional biochemical assays, cell-based assays are physiologically relevant and can determine complex features concurrently.

Key Insights

• As per the analysis shared by our research analyst, the global cell-based assays market is projected to expand annually at the annual growth rate of around 12.4% over the forecast timespan (2023-2030)
• In terms of revenue, the global cell-based assays market was evaluated at nearly $16.3 billion in 2022 and is expected to reach $26.5 billion by 2030.
• The global market is anticipated to record massive growth over the forecast period owing to the use of cell-based assays in the drug development process.
• Based on product & service, the assay kits segment is predicted to contribute majorly towards the market growth over the forecast timeline.
• In terms of application, the drug discovery segment is projected to account for a major share of the global market in 2023-2030.
• On the basis of the end-use, the pharmaceutical & biotech companies segment is projected to account for a major share of the global market in 2023-2030.
• Region-wise, the Asia-Pacific cell-based assay market is projected to register the fastest CAGR during the assessment period.

Request Free Sample

Cell-Based Assays Market: Growth Factors

Ability to offer effective and inexpensive drug solutions to end-user to boost the global market trends

Cell-based assays are major parts of the drug development process and have several components in the drug development procedures. In addition to this, these assays provide constant tissue-specific responses in a biologically controlled environment. All these aspects will steer the growth of the global cell-based assays market. In addition to this, pharma & biotech firms and CROs make use of cell-based assays for lead detection and optimization procedures in drug discovery, thereby charting a profitable roadmap for the global cell-based assays market.

The overall production costs of biopharmaceuticals have increased notably and hence healthcare service providers prefer the use of cell-based assay. This, in turn, will drive the global market trends.

Furthermore, traditional procedures of toxicity and assessing drug safety are costly and time-consuming and provide low throughput, thereby steering the demand for cell-based assays. In addition to this, the physiological significance of cell-based assays and their ability to provide proficient, cost-efficient, and effective drug solutions has prompted the acceptance of cell-based assays among customers.

Cell-Based Assays Market: Restraints

High device costs can hinder the global industry demand

Huge equipment costs and restricted use of reagents can put brakes on the global cell-based assays industry growth in the upcoming years. Furthermore, huge maintenance charges and indirect expenditures as well as a rise in the overall ownership costs of equipment can hinder the growth of the industry across the globe.

Cell-Based Assays Market: Challenges

Shifting government regulations can put a huge challenge in the growth path of the global market

Changing government laws and high transportation costs can prove to be a challenging task for the growth of the global cell-based assays market.

Cell-Based Assays Market: Opportunities

Huge investment in research activities related to biotech research to open new growth opportunities for the global industry

Developing economies of Asia having low-wage labor and reduced raw component costs are projected to generate new growth avenues for the global cell-based assays industry. Rise in the allocation of funds for research & development projects pertaining to biotech activities will open new growth horizons for the industry across the globe.

Cell-Based Assays Market: Segmentation

The global cell-based assays market is sectored into product & service, application, end-user, and region.   

In terms of product & service, the global cell-based assays market is sectored into reagents, cell lines, instrument & software, assay kits, microplate, and service segments. Furthermore, the assay kits segment, which accounted for more than 35% of the global market share in 2022, is anticipated to retain its segmental domination even during 2023-2030. The segmental surge in the next eight years can be attributed to its humungous application in the biopharmaceutical sector.

Based on the application, the global cell-based assays industry is divided into basic research and drug discovery segments. The drug discovery segment, which dominated the application segment in 2022, is set to account for a major industry share over the forecast timeline. The growth of the segment in the coming years can be due to the escalating demand for new therapeutic medicines for treating various diseases globally. The expansion of the drug discovery segment is likely to receive a further boost owing to an increase in the number of FDA approvals of newly discovered drugs, particularly generic ones.

On the basis of end-use, cell-based assays industry across the globe is sectored into pharmaceutical & biotech companies, academic & research institutes, and CROs segments. Moreover, the pharmaceutical & biotech companies segment, which contributed more than half of the global market revenue in 2022, is projected to retain its segmental dominance even in the coming years. The growth of the segment in the next couple of years can be attributed to the ability of cell-based assays in the assessment of external stimuli in pharmacological molecules.

Recent Breakthroughs:

• In the first half of 2020, PhenoVista Biosciences, a U.S.-based CRO firm in in-vitro cell-based assays business, entered into a strategic partnership with Olympus Corporation, a Japan-based firm producing reprography & optics items, for delivering 3D cell-based assay solutions for drug discovery. The strategic initiative is likely to embellish the expansion of the cell-based assays market across the globe.
• In the third quarter of 2022, Life Net Health Lifesciences, a key firm providing new human cell & tissue-based solutions for biomedical research to develop next-gen treatments, introduced cell-based assays including biocompatibility assays and cytotoxicity screening tests. The move will contribute substantially towards the expansion of the cell-based assays industry size in the years to come.
• In the first half of 2022, Beckman Coulter Life Sciences, a key Danaher firm focusing on healthcare solutions, introduced the Aquios STEM system which offers a new solution for research on stem cells. The move is likely to benefit the growth of the cell-based assays market in the forthcoming years.

Cell-Based Assays Market: Report Scope

Cell-Based Assays Market: Regional Insights

North American cell-based assays market to accrue major gains over the next eight years

North America, which accounted for over 43% of the global cell-based assays market revenue in 2022, is anticipated to dominate regional market expansion over the analysis period. The regional market elevation over 2023-2030 can be a result of widespread research on cell-based assays in the countries such as the U.S. and Canada. Presence of reputed academic research institutes and pharmaceutical firms in the sub-continent will contribute notably towards the regional market growth.

On the other hand, the cell-based assays industry in the Asia-Pacific region is predicted to register the fastest CAGR in the forecasting period. The growth of the market in the region can be ascribed to swift infrastructural growth and a rise in funding of biotech research activities by the public and private sectors.

Cell-Based Assays Market: Competitive Space

The cell-based assays market profiles key players such as:

• Charles River Laboratories
• F. Hoffmann-La Roche Ltd. (Roche Holdings AG)
• BD
• Promega Corp.
• Merck KGaA
• Corning Inc.
• Bio-Rad Laboratories Inc.
• Lonza AG
• Danaher Corp.

The global cell-based assays market is segmented as follows:

By Product & Service

• Reagents
• Cell Lines
• Instrument & Software
• Assay Kits
• Microplate
• Services

By Application

• Basic Research
• Drug Discovery

By End-Use

• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• CROs

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa